BRIEF-Redhill Biopharma says re-submission of rizaport U.S. NDA expected in Q4 of 2016
* Re-Submission of rizaport U.S. New drug application (NDA) to FDA and receipt of a new pdufa date are expected in Q4 of 2016 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
No comments:
Post a Comment